期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 19, 期 18, 页码 5480-5489出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2011.07.046
关键词
Peptide; Paclitaxel; Lung cancer; Drug delivery
资金
- Welch Foundation [I1622]
- Specialized Program of Research Excellence in Lung Cancer [P50CA70907]
- Cancer Research and Prevention Institute of Texas [RP 101496)]
The integrin alpha(v)beta(6) is an emergent biomarker for non-small cell lung cancer (NSCLC) as well as other carcinomas. We previously developed a tetrameric peptide, referred to as H2009.1, which binds alpha(v)beta(6) and displays minimal affinity for other RGD-binding integrins. Here we report the use of this peptide to actively deliver paclitaxel to alpha(v)beta(6)-positive cells. We synthesized a water soluble paclitaxel-H2009.1 peptide conjugate in which the 2'-position of paclitaxel is attached to the tetrameric peptide via an ester linkage. The conjugate maintains its specificity for alpha(v)beta(6)-expressing NSCLC cells, resulting in selective cytotoxicity. Treatment of alpha(v)beta(6)-positive cells with the conjugate results in cell cycle arrest followed by induction of apoptosis in the same manner as free paclitaxel. However, initiation of apoptosis and the resultant cell death is delayed compared to free drug. The conjugate demonstrates anti-tumor activity in a H2009 xenograft model of NSCLC with efficacy comparable to treatment with free paclitaxel. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据